Understanding how fibrotic tissue affects breast cancer treatment and stability
Fibrotic extracellular matrix: uncovering its role in breast cancer genome stability and metabolic plasticity
This study is looking at how the tough tissue around breast cancer cells affects their ability to stay stable and resist treatments, especially in tougher cases like triple-negative breast cancer, to help find better ways to fight the disease.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-10876405 on NIH RePORTER |
What this research studies
This research investigates the role of fibrotic extracellular matrix (ECM) in breast cancer, particularly focusing on how it influences the stability of the cancer genome and the resistance to therapies. The study aims to explore the interactions between the tumor microenvironment and cancer cells, using advanced 3D tissue culture systems to simulate real tumor conditions. By examining how fibrotic ECM affects DNA damage response and metabolic processes in breast cancer cells, the research seeks to uncover new mechanisms that contribute to treatment resistance, especially in aggressive forms of breast cancer like triple-negative breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer, especially those with triple-negative breast cancer or those experiencing therapeutic resistance.
Not a fit: Patients with non-breast cancer conditions or those whose cancer is not influenced by the tumor microenvironment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for breast cancer patients, particularly those with treatment-resistant forms of the disease.
How similar studies have performed: While the specific focus on fibrotic ECM in breast cancer is relatively novel, there have been successful studies exploring the tumor microenvironment's role in cancer treatment resistance.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Moore, Elizabeth S — Cornell University
- Study coordinator: Moore, Elizabeth S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.